Company intelligence / Profile preview

StemCyte India Therapeutics

Gandhinagar, Gujarat, India

Ownership: Private
Development stage: Other

Overview

StemCyte India operates clinical trials for umbilical cord blood stem cell therapies. The parent company StemCyte has facilitated over 2,000 cord blood transplants globally, with StemCyte India specifically facilitating 43 transplants as of the most recent data. The company's lead product uses allogeneic cord blood hematopoietic progenitor cells, with Phase II trials underway for Post-COVID Syndrome and Phase III development status noted for certain indications.

Therapeutic areas: HematologyCardiovascularNeurologyInfectious Diseases
Modalities: Stem cell therapyCell therapy
Industry: Biotech

Partnerships

Apollo Hospital Enterprises Ltd.Cadila Pharmaceuticals Ltd.

Beyond the preview

Go deeper on StemCyte India Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemCyte India Therapeutics.

Explore the full profile